Chronic Obstructive Pulmonary Disease (COPD) Market Growth, Size, Trends Analysis- By Type, By Treatment Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Chronic Obstructive Pulmonary Disease (COPD) Market Introduction and Overview

According to SPER Market Research, 'Global Chronic Obstructive Pulmonary Disease (COPD) Market Size- By Type, By Treatment Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' states that the Global Chronic Obstructive Pulmonary Disease (COPD) Market is estimated to reach USD 33.31 billion by 2033 with a CAGR of 4.68%.

Chronic obstructive pulmonary disease (COPD), a degenerative lung disease, is characterized by persistent respiratory symptoms and airflow restriction. It encompasses conditions like emphysema and chronic bronchitis that are primarily caused by long-term exposure to harmful gases or particles, most commonly by smoking. Coughing, wheezing, and increased mucus production are all symptoms of the illness's inflammation and destruction to the lung tissue and airways, which makes breathing difficult.

The global market for chronic obstructive pulmonary disease (COPD) has been significantly impacted by the COVID-19 pandemic, presenting both potential and challenges. Because of their underlying respiratory disorders, those with COPD were more vulnerable during the pandemic, leading to an increase in hospitalizations and a focus on respiratory health. Prioritizing COVID-19 responses often caused healthcare systems to disrupt regular care and management of COPD, which impacted patients' access to medications and made their illnesses worse.

Scope of the report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Type, By Treatment Type, By End User

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Pfizer Inc, Merck & Co., Inc, Novartis AG, AstraZeneca, GlaxoSmithKline plc, Roche (F. Hoffmann-La Roche Ltd, Switzerland), Abbott, Boehringer Ingelheim International GmbH, Biogen, Teva Pharmaceutical Industries Ltd, Others.

Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation:

By Type: Based on the Type, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Chronic Bronchitis, Emphysema.

By Treatment Type: Based on the Treatment Type, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Bronchodilator monotherapy, short-acting beta2-agonists (SABAs), long-acting beta2-agonists (LABAs), anti-cholinergic agents, anti-inflammatory drugs, oral and inhaled corticosteroids, anti-leukotrienes, surgery, lung volume reduction surgery (LVRS), lung transplant, bullectomy and others.

By End User: Based on the End User, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Hospitals, Homecare Settings, Clinics, Others

By Region: This research also include data for North America, Europe, Asia-Pacific Middle East & Africa and South America.

Product Code: PHAR2417

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Chronic Obstructive Pulmonary Disease (COPD) Market.

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Chronic Obstructive Pulmonary Disease (COPD) Market

7. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By Type (USD Million) 2020-2033

7.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Type, 2020-2026
7.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Type, 2027-2033
7.3. Chronic Bronchitis
7.4. Emphysema

8. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By Treatment Type (USD Million) 2020-2033

8.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Treatment Type, 2020-2026
8.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Treatment Type, 2027-2033
8.3. Drugs
8.4. Bronchodilator Monotherapy
8.5. Short-Acting Beta2-Agonists (SABAS)
8.6. Long-Acting Beta2-Agonists (LABAS)
8.7. Anti-Cholinergic Agents
8.8. Anti-Inflammatory Drugs
8.9. Oral And Inhaled Corticosteroids
8.10. Anti-Leukotrienes
8.11. Surgery
8.12. Lung Volume Reduction Surgery (LVRS)
8.13. Lung Transplant, Bullectomy
8.14. Others

9. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By End User (USD Million) 2020-2033

9.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By End User, 2020-2026
9.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By End User, 2027-2033
9.3. Hospitals
9.4. Homecare Settings
9.5. Clinics
9.6. Others

10. Global Chronic Obstructive Pulmonary Disease (COPD) Market Forecast, 2020-2033 (USD Million)

10.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Market Share

11. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By Region, 2020-2033 (USD Million)

11.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Market Share By Region (2020-2026)
11.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
- 11.3.1. Australia
- 11.3.2. China
- 11.3.3. India
- 11.3.4. Japan
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
11.4. Europe
- 11.4.1. France
- 11.4.2. Germany
- 11.4.3. Italy
- 11.4.4. Spain
- 11.4.5. United Kingdom
- 11.4.6. Rest of Europe
11.5. Middle East and Africa
- 11.5.1. Kingdom of Saudi Arabia
- 11.5.2. United Arab Emirates
- 11.5.3. Qatar
- 11.5.4. South Africa
- 11.5.5. Egypt
- 11.5.6. Morocco
- 11.5.7. Nigeria
- 11.5.8. Rest of Middle-East and Africa
11.6. North America
- 11.6.1. Canada
- 11.6.2. Mexico
- 11.6.3. United States
11.7. Latin America
- 11.7.1. Argentina
- 11.7.2. Brazil
- 11.7.3. Rest of Latin America

12. Company Profile

12.1. Pfizer Inc
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Merck & Co., Inc
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Novartis AG
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. AstraZeneca
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. GlaxoSmithKline plc
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Roche (F. Hoffmann-La Roche Ltd, Switzerland)
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Abbott
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Boehringer Ingelheim International GmbH
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Biogen
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Teva Pharmaceutical Industries Ltd
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Others